Pfizer Inc Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Transcript
Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to discuss the Pfizer-BioNTech COVID-19 vaccine and Pfizer's novel COVID-19 oral antiviral treatment candidate. Today's call is being recorded.
At this time, I would like to turn the call over to Mr. Chris Stevo, Senior Vice President and Chief Investor Relations Officer. Please go ahead, sir.
Thank you, Sophia. Good morning, everyone. I'd like to welcome you all to Pfizer's investor event to discuss our COVID-19 vaccines and therapeutics franchise.
Presentation at today's investor event includes forward-looking statements about, amongst other things, our efforts to combat COVID-19, including our development of a vaccine to help prevent COVID-19 and our investigational protease inhibitors, our anticipated future operating and financial performance, business plans and prospects and expectations for our in-line products and product candidates.
By their nature, all statements about future events and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |